Hot Takes
Fast editorial commentary on emerging health and medical research. Hot Takes are published faster than the standard medical-review cycle so we can keep up with news that matters to people thinking about their lab work. Each one is clearly labeled and dated.
- Hot TakePublished June 2, 2026
A New Gonorrhea Strain Is Causing Bloodstream Infections in Minnesota. Routine Testing Is the Off-Ramp.
Editorial commentary on Emerging Infectious Diseases (CDC), May 19, 2026
Minnesota Department of Health and CDC researchers describe a new Neisseria gonorrhoeae strain, ST16676, behind 26 of 28 disseminated gonococcal infections in the state in 2025. Routine NAAT-based STD testing catches gonorrhea at the mucosal stage, long before it can spread to the bloodstream.
- Hot TakePublished June 1, 2026
GRAIL Galleri Multi-Cancer Blood Test Cuts Stage IV Diagnoses in NHS Trial
Editorial commentary on American Society of Clinical Oncology Annual Meeting 2026 / GRAIL, May 31, 2026
The full NHS-Galleri trial results presented at ASCO 2026 missed the primary endpoint of cutting combined stage III and IV cancers, but cut stage IV diagnoses by more than 20 percent in the second and third screening rounds. The takeaway is genuinely mixed.
- Hot TakePublished May 30, 2026
GLP-1 Drugs Linked to Lower Metastasis Risk in Obesity-Related Cancers
Editorial commentary on Moffitt Cancer Center / American Society of Clinical Oncology 2026 Annual Meeting, May 29, 2026
An ASCO 2026 study of more than 12,000 patients linked GLP-1 drugs like semaglutide and tirzepatide to a 38 to 50 percent lower risk of metastatic disease in four obesity-related cancers compared with DPP-4 inhibitor users. The finding is observational, not causal.
- Hot TakePublished May 29, 2026
WHO Issues First Global Doxy-PEP Recommendation, With Mandatory Testing Built In
Editorial commentary on World Health Organization, May 28, 2026
The World Health Organization's May 28, 2026 doxy-PEP guidance is the first global recommendation of its kind. It bakes quarterly syphilis serology and bacterial STI panel testing into the protocol as required components, not optional add-ons.
- Hot TakePublished May 26, 2026
BMJ Meta-Analysis: Calcium and Vitamin D Do Little for Fractures in Average-Risk Older Adults
Editorial commentary on BMJ, May 21, 2026
A May 2026 BMJ meta-analysis of 69 trials and nearly 154,000 adults concluded that calcium, vitamin D, or both, given to average-risk older adults, offer little to no clinically meaningful benefit for fracture or fall prevention. The case for testing first instead of supplementing blindly is getting stronger.
- Hot TakePublished May 25, 2026
DoxyPEP May Be Losing Its Edge Against Gonorrhea, New Study Finds
Editorial commentary on The Lancet Infectious Diseases, May 7, 2026
A May 7, 2026 study in The Lancet Infectious Diseases found that doxyPEP protection against gonorrhea dropped sharply in Southern California as tetracycline-resistant strains spread, while protection against chlamydia and syphilis held.
- Hot TakePublished May 22, 2026
American Cancer Society Adds Blood Test to Colorectal Screening Options
Editorial commentary on American Cancer Society, May 21, 2026
The American Cancer Society's May 2026 update adds the Shield blood test to its colorectal cancer screening options. It is a real addition with real limits: lower sensitivity for precancerous polyps than colonoscopy or stool tests.
- Hot TakePublished May 20, 2026
Lp(a) Is an Independent Cardiovascular Risk Factor, And the VESALIUS-CV Data Just Reinforced It
Editorial commentary on Circulation / VESALIUS-CV Trial, May 12, 2026
VESALIUS-CV in Circulation, May 2026, found that Lp(a) is independently linked to major coronary events in primary-prevention patients with atherosclerosis or high-risk diabetes. The case for measuring it at least once in adulthood keeps getting stronger.
- Hot TakePublished May 18, 2026
FDA Approves Baxfendy for Resistant Hypertension. The Lab Story Behind It.
Editorial commentary on U.S. Food and Drug Administration / AstraZeneca, May 15, 2026
Baxfendy is a first-in-class aldosterone synthase inhibitor approved May 15, 2026 for difficult-to-control high blood pressure. The lab-relevant part of the story is how it changes ongoing electrolyte and kidney monitoring.
- Hot TakePublished May 16, 2026
ApoB Outperforms LDL for Guiding Cholesterol Therapy, New JAMA Study Finds
Editorial commentary on JAMA / Northwestern Medicine, May 13, 2026
A May 2026 JAMA Northwestern Medicine simulation found ApoB-guided cholesterol therapy outperformed LDL or non-HDL-guided care across a lifetime and was cost-effective. ApoB is finally getting its due.
- Hot TakePublished May 14, 2026
FDA Clears Onclarity HPV At-Home Self-Collection. The Cervical Screening Landscape Just Widened Again.
Editorial commentary on U.S. Food and Drug Administration / BD, April 23, 2026
The FDA cleared Onclarity's at-home HPV self-collection kit in April 2026, a year after Teal Wand. Cervical cancer screening at home is no longer a single-player market.
- Hot TakePublished May 11, 2026
High Lifelong Testosterone Linked to Coronary Artery Disease in Men, New Cambridge Study
Editorial commentary on University of Cambridge, February 10, 2026
A 2026 Cambridge genetic study of 1.4 million people found that men with gene variants linked to higher lifelong testosterone had a 17 percent greater risk of coronary artery disease, largely mediated by higher blood pressure. The finding is about endogenous testosterone, not TRT.
- Hot TakePublished May 7, 2026
What Blood Tests Do Astronauts Get? A Look at NASA Health Monitoring
Editorial commentary on NASA Human Research Program, May 7, 2026
A source-guided editorial explainer on the bloodwork and broader health monitoring NASA describes for astronauts before, during, and after spaceflight — and why ordinary consumer labs are not an astronaut program in miniature.
- Hot TakePublished April 25, 2026
PSA Screening and Age: New Study Maps Overdiagnosis Risk
Editorial commentary on International Journal of Cancer, April 22, 2026
A new International Journal of Cancer study quantifies how PSA screening's overdiagnosis risk climbs with age, from 16% at 50 to 58% at 80. The data reinforces a clear age window where screening is most useful.